Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)
研究概览
详细说明
OBJECTIVES:
I. Determine treatment effectiveness of gefitinib, in terms of response rate, time to progression, survival at 52 weeks, progression-free survival at 6 months, and overall survival, in patients with newly diagnosed glioblastoma multiforme.
II. Determine the toxic effects of this drug in these patients. III. Assess fatigue, depression, excessive daytime somnolence, and quality of life in patients treated with this drug.
IV. Assess individual variation in responses, pharmacokinetic parameters, and/or biological correlates due to genetic differences in enzymes involved in transport, metabolism, and/or mechanism of action of this drug in these patients.
V. Determine if the type of epidermal growth factor receptor affects tumor response and outcome in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.
Patients are followed every 8 weeks until tumor progression and then every 3 months for 5 years and annually for up to 10 years. Patients removed from study treatment for reasons other than disease progression are followed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.
PROJECTED ACCRUAL: A total of 92 patients will be accrued for this study within 14 months.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- North Central Cancer Treatment Group
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Histologically confirmed newly diagnosed WHO grade IV astrocytoma (glioblastoma multiforme) or gliosarcoma
- No WHO grade III anaplastic astrocytoma, oligodendroglioma, or mixed oligoastrocytoma
Completed standard external beam radiotherapy within the past 2-5 weeks
- No evidence of tumor progression during radiotherapy
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10.0 g/dL
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST no greater than 3 times ULN
- Creatinine no greater than 1.5 times ULN
- No other active malignancy
- No uncontrolled infection
- No other severe concurrent disease that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior chemotherapy (including polifeprosan 20 with carmustine implant) for this tumor
- See Disease Characteristics
- No prior stereotactic radiosurgery or interstitial brachytherapy
- No more than 15 weeks since prior surgery
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment (gefitinib)
Patients receive oral gefitinib daily.
Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
|
相关研究
口头给予
其他名称:
辅助研究
辅助研究
其他名称:
相关研究
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Survival
大体时间:52 weeks
|
The proportion of 'successes' will be estimated using the binomial point estimator (number of 'successes' divided by the total number of evaluable patients) and standard binomial 90% confidence interval estimates.
In the unlikely event that accrual has not been completed before the interim analyses are performed, the Duffy-Santner lgorithm will be used to calculate 90% confidence intervals.
|
52 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Post-RT progression-time
大体时间:From start of study therapy to date of disease progression or last follow-up, assessed up to 10 years
|
Kaplan-Meier survival curves and logrank tests will be used.
|
From start of study therapy to date of disease progression or last follow-up, assessed up to 10 years
|
Toxicity patterns assessed using NCI CTC version 2.0
大体时间:Up to 10 years
|
Will be analyzed descriptively.
Toxicity score calculated as the sum of the maximum toxicity grades recorded for each of the types of adverse reactions observed during the trial.
|
Up to 10 years
|
合作者和调查者
调查人员
- 首席研究员:Joon Uhm、North Central Cancer Treatment Group
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
实验室生物标志物分析的临床试验
-
ORIOL BESTARD完全的
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)尚未招聘艾滋病毒感染 | 乙型肝炎
-
Hvidovre University HospitalElsassFonden终止
-
Fundació Sant Joan de DéuStanley Medical Research Institute; Parc Sanitari Sant Joan de Déu; Hospital Sant Joan de Deu完全的